Matrixyl

Matrixyl was developed by Sederma (now Croda) and launched in 2000, becoming one of the most commercially successful cosmetic peptides ever created. The KTTKS sequence is derived from the alpha-1 chain of type I procollagen — a peptide signal generated during normal collagen remodeling that communicates to fibroblasts that repair and replacement synthesis is needed.

The palmitic acid conjugation (creating "Pal-KTTKS") dramatically enhances skin penetration through the stratum corneum by increasing lipophilicity, allowing the peptide to reach dermal fibroblasts. In a double-blind, vehicle-controlled trial published in the International Journal of Cosmetic Science, 2% Matrixyl significantly reduced wrinkle volume, depth, and roughness versus vehicle after 12 weeks of twice-daily application.

// MATRIKINE SIGNALING

The KTTKS sequence is a matrikine — a biologically active peptide fragment released from the extracellular matrix during tissue remodeling. By mimicking this signal, Matrixyl activates TGF-β1 and fibronectin receptor pathways in dermal fibroblasts, upregulating expression of collagen type I and III, elastin, and fibronectin.

// MMP REGULATION

Matrixyl also modulates matrix metalloproteinase (MMP) activity — increasing MMP-1 (collagenase) to facilitate remodeling of damaged, cross-linked collagen while simultaneously stimulating new collagen deposition. This net turnover effect progressively replaces aged, disorganized collagen with aligned, functional fibers.